Graves disease following rabbit antithymocyte globulin treatment of severe aplastic anemia in a Korean child

In Su Choi, MD, Han Kyul Kim, MD, Dong Kyun Han, MD, Hee Jo Baek, MD, Hae In Jang, MD, Chan Jong Kim, MD, Hoon Kook, MD
Department of Pediatrics, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju, Korea

Antithymocyte globulin (ATG) is used as an immunosuppressive treatment (IST) to deplete clonal suppressor T cells in patients with severe aplastic anemia (SAA). The depletion of suppressor T cells by ATG may affect the activation of B cells, which results in an increased risk for autoimmune conditions. A 12-year-old boy was diagnosed with idiopathic SAA. As he did not have an human leukocyte antigen-matched sibling, he was treated with rabbit ATG (3.5 mg/kg/day for 5 days) and cyclosporine. Five months later, he became transfusion independent. However, 23 months after IST, he complained of mild hand tremors, sweating, weight loss, palpitations, and goiter. Results of thyroid function tests revealed hyperthyroidism (free thyroxine, 3.42 ng/dL; thyroid stimulating hormone [TSH], <0.01 nIU/mL; triiodothyronine, 3.99 ng/mL). Results of tests for autoantibodies were positive for the antimicrosome antibody and TSH-binding inhibitory immunoglobulin, but negative for the antithyroglobulin antibody and antinuclear antibody. He was treated with methimazole, and his symptoms improved. The patient has been disease free for 39 months after IST and 9 months after methimazole treatment. This case report suggests that although rare, rabbit ATG may have implications in the pathogenesis of autoimmune hyperthyroidism. Our findings suggest that thyroid function tests should be incorporated in the routine follow-up of SAA patients treated with ATG.

Key words: Graves disease, Antithymocyte serum, Aplastic anemia, Child

Introduction

Severe aplastic anemia (SAA) is a fatal disease characterized by pancytopenia and hypocellular bone marrow. Bone marrow transplantation is the treatment of choice for young patients who have a human leukocyte antigen (HLA) matched sibling donor. Immunosuppressive treatment (IST) with antithymocyte globulin (ATG) and cyclosporine is an effective therapy for patients who have no suitable donor. ATG exerts its action by depleting clonal suppressor T cells implicated in the pathogenesis of SAA.\(^1\)\(^-\)\(^3\) The depletion of suppressor T cells by ATG could change the B-cell activation\(^1\)\(^-\)\(^3\). Therefore this treatment might increase the risk of autoimmune phenomena. There have been rare reports on the association between ATG treatment for SAA and the development of autoimmune hyperthyroidism.\(^4\)\(^-\)\(^6\)

Because horse ATG (hATG) is no longer available for the treatment of SAA in most countries, rabbit ATG (rATG) is the only preparation currently available.\(^8\) Moreover, as rATG has more potent and prolonged suppression of T cells than hATG, more frequent encounters of autoimmune hyperthyroidism can be anticipated. We report the rare case of Graves disease following rATG treatment for SAA in a Korean child.
Case report

A 12-year-old boy visited Chonnam National University Hwasun Hospital because of petechiae, easy bruising and knee joint pain in December 2007. There was no relevant past medical history. A complete blood count showed white blood cell 1,600/μL, hemoglobin 11.7 g/dL, platelets 4,000/μL, absolute neutrophil count 940/μL, and corrected reticulocyte count 0.89%. A bone marrow biopsy showed a hypopcellular fatty marrow (cellularity <10%). Chromosome breakage test was negative. Cytogenetics was normal. Flow cytometry analyses for paroxysmal nocturnal hemoglobinuria were negative. The patient was diagnosed as a SAA. As he had no HLA-matched sibling, he was treated with IST using rATG (Thymoglobuline, Genzyme, Cambridge, MA, USA; 3.5 mg/kg/day for 5 days) and cyclosporine (5 mg/kg/day) and methylprednisolone (2 mg/kg/day for 5 days, then tapered over 30 days). While being treated with IST, he developed peripheral neuropathy with pain and tingling sensation in both extremities, requiring a sympathetic nerve block, which relieved symptoms. Five months after the IST, he became transfusion independent. Twenty-three months after IST with rATG, he complained of mild hand tremors, sweating, weight loss, palpitations and goiter. Subsequent thyroid function tests showed the hyperthyroidism (free thyroxine, 3.42 ng/dL; TSH, <0.01 nIU/mL; triiodothyronine, 3.99 ng/mL; thyroxine, 17.3 μg/dL). Autoantibody results were as follows: antimicrosome antibody (+), TSH-binding inhibitory immunoglobulin (+), antithyroglobulin antibody (–), and antinuclear antibody (–). Thyroid ultrasonography showed diffuse thyroid enlargement with multiple benign nodules (Fig. 1A). A Tc-99m pertechnetate thyroid scan showed enlarged thyroid gland with diffuse uptake (Fig. 1B). Thus, he was diagnosed with Graves disease. He was treated with methimazole and the symptoms improved. The patient has been disease free 39 months after IST and 9 months after methimazole treatment. Currently, his blood counts and thyroid function tests are normal, and he has no discomfort from Graves disease.

Discussion

Graves disease is an autoimmune disorder characterized by hyperthyroidism, diffuse goiter, ophthalmopathy, and occasionally a dermopathy referred to as pretibial or localized myxedema. In immune pathogenesis of Graves disease, B and T cells have a major role in the production of TSH receptor antibodies (TSHR-Ab) that are responsible for the thyroid stimulation and growth. T cells are present in the immune repertoire of patients with Graves disease. These activated T cells in turn increase the secretion of TSHR-Ab from B cells. The hyperthyroidism and goiter of Graves disease are caused by stimulation of the thyroid by TSHR-Ab. It has been suggested that a genetic clonal lack of suppressor T cells may be responsible for the unregulated production of TSHR-Ab in in vitro studies.

The pathogenesis of aplastic anemia is thought to be T-cell-mediated destruction of hematopoietic progenitors and stem cells. A variety of in vitro and in vivo research supported the implication of immune effector cells and cytokines, such as interferon-γ or tumor necrosis factor-α. The mechanism action of ATG therapy for aplastic anemia is likely complex and multifactorial, but its main mechanism is thought to have immunosuppressive effect by depleting peripheral T cells from the circulation through complement-dependent lysis or activation associated apoptosis. ATG is manufactured through the immunization of horses or rabbits with thymocytes or T-cell lines, followed by the purification of the IgG fraction of the sera from these animals. Between hATG and rATG preparations, there are differences.
in pharmacologic properties, antibody specificity and binding capacity. Thus, they are dissimilar in inducing activation of T cells, as exemplified in the case of expansion of regulatory T cells\textsuperscript{11}. Also, gene expression profiling was markedly different between cells treated with both preparations\textsuperscript{11}. As a consequence, hATG and rATG would provide different mechanisms of action through multiple modes of immunomodulation. Despite the differences mentioned above, hATG and rATG have generally been used interchangeably in the clinic. However, in a recent randomized, prospective trial, rATG plus cyclosporine compared unfavorably with hATG plus cyclosporine when used as a first-line treatment. These results were unexpected, given that rATG is more immuno-suppressive than hATG\textsuperscript{12,13}. The use of rATG led to a more profound depletion of CD4+ T cells, whereas both preparations resulted in a similar depletion of CD8+ T cells\textsuperscript{8}.

The depletion of suppressor T cells by ATG was thought to have a role in the development of many autoimmune disorders\textsuperscript{3}. Interferon-\(\gamma\) is vital for cell-mediated immunity, inhibition of inappropriate B-cell proliferation and antibody production. It is secreted by a subset of suppressor T cells to inhibit Th2-cells which in turn activate B cells\textsuperscript{13}. Thus, depletion of suppressor T cells and resultant decreased production of interferon-\(\gamma\) by ATG could also allow B-cell activation, which increases the risk of autoimmune disorder. This was supported by studies showing that interferon-\(\gamma\) down-regulates TSHR-Ab production\textsuperscript{14}. It also attenuated TSH receptor (the TSHR-Ab target) synthesis in Graves disease\textsuperscript{15}. Thus, impaired interferon-\(\gamma\) production can cause derestricted TSHR-Ab production and increased TSH receptor production, resulting in immune hyperthyroidism.

There are a few reports of Graves disease after treatment with ATG for SAA\textsuperscript{4-7}. Three cases have been described occurring 26, 42, and 106 months after treatment with antilymphocyte globulin or ATG in patients aged 25, 30, and 35 years, respectively\textsuperscript{8}. A 62-year-old man developed Graves disease and fibrosing alveolitis 15 days after the administration of ATG for SAA\textsuperscript{9}. The first case in children was described 6 years after ATG in a 10-year-old boy\textsuperscript{9}. All the reported cases in the literature were treated with horse preparations.

This case represents the first case of possible implication of rATG in the pathogenesis of autoimmune hyperthyroidism. Recently, hATG is no longer available for the treatment of SAA in Europe, Japan, Latin America, and Korea. Moreover, rATG has more potent and prolonged suppression of T cells than hATG\textsuperscript{8}, and the development of autoimmune hyperthyroidism may be encountered more frequently. However, the incidence and exact mechanism underlying the association should be elucidated. Therefore, thyroid function tests should be incorporated in the routine follow-up of SAA following rATG treatment.

### Conflict of interest

No potential conflict of interest relevant to this article was reported.

### References

1. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006;108: 2509-19.
2. Killibck SB, Marsh JC, Gordon-Smith EC, Sorlin L, Gibson FM. Effects of antithymocyte globulin on bone marrow CD34+ cells in aplastic anaemia and myelodysplasia. Br J Haematol 2000;108: 582-91.
3. Teramura M, Kobayashi S, Iwabe K, Yoshinaka K, Mizoguchi H. Mechanism of action of antithymocyte globulin in the treatment of aplastic anemia: in vitro evidence for the presence of immunosuppressive mechanism. Br J Haematol 1997;96:80-4.
4. Todd A, Todd J. Graves' disease following successful treatment of severe aplastic anaemia with antilymphocyte globulin. Clin Lab Haematol 1999;21:69-70.
5. Zomas A, Marsh JC, Harrison NK, Hyer SL, Nussey SS, Knee G, et al. Rapid progression of fibrosing alveolitis and thyrotoxicosis after antithymocyte globulin therapy for aplastic anemia. Ann Hematol 1995;71:49-51.
6. Hinterberger-Fischer M, Kier P, Forstinger I, Lechner K, Kornek G, Breyer S, et al. Coincidence of severe aplastic anaemia with multiple sclerosis or thyroid disorders: report of 5 cases. Acta Haematol 1994;92:136-9.
7. Kumar M, Goldman J. Severe aplastic anaemia and Grave's disease in a paediatric patient. Br J Haematol 2002;118:327-9.
8. Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Biancotto A, Wu CO, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med 2011;365:430-8.
9. Ginsberg J. Diagnosis and management of Graves' disease. Can Med Assoc J 2003;168:575-85.
10. Volpe R. The immunoregulatory disturbance in autoimmune thyroid disease. Autoimmunity 1988;2:55-72.
11. Feng X, Kajigaya S, Solomon EE, Keyvanfar K, Xu X, Raghavachari N, et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25\textsuperscript{hi}FOXP3+ regulatory T cells in vitro. Blood 2008;111:3675-83.
12. Scheinberg P, Fischer SH, Li L, Nunez O, Wu CO, Slaend EM, et al. Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anaemia. Blood 2007;109:3219-24.
13. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 2004;75:163-89.
14. Yoshikawa N, Mori S, Tokoro T, Ikehara S, Kumazawa H, Yamashita T, et al. IFN-gamma has a protective role against thyroid-specific autoantibody production in severe combined immunodeficient (SCID) mice xenografted with Graves' thyroid tissue. Thyroid 1996; 6:437-43.
15. Nishikawa T, Yamashita S, Namba H, Uda T, Tominaga T, Kimura H, et al. Interferon-gamma inhibition of human thyrotropin receptor gene expression. J Clin Endocrinol Metab 1993;77:1084-9.